Arthur Frankel, M.D., received his initial medical training at Harvard University. He completed a research postdoctoral fellowship at the NIH and residency and medical oncology fellowship at Stanford University. He is board certified in hematology and medical oncology and has a strong clinical background in general medical oncology, and benign and malignant hematology. His research focus is the preclinical and clinical development of targeted cancer therapeutics. He leads the Phase 1 Clinical Trials unit at UT Southwestern.